Logo image of SCPS

SCOPUS BIOPHARMA INC (SCPS) Stock Fundamental Analysis

USA - NASDAQ:SCPS - US8091711015 - Common Stock

0.1682 USD
-0.17 (-50.54%)
Last: 12/16/2022, 8:25:53 PM
0.12 USD
-0.05 (-28.66%)
After Hours: 12/16/2022, 8:25:53 PM
Fundamental Rating

0

SCPS gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. SCPS may be in some trouble as it scores bad on both profitability and health. SCPS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SCPS had negative earnings in the past year.
In the past year SCPS has reported a negative cash flow from operations.
SCPS Yearly Net Income VS EBIT VS OCF VS FCFSCPS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 -5M -10M -15M -20M -25M

1.2 Ratios

SCPS has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SCPS Yearly ROA, ROE, ROICSCPS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 0 2K 4K 6K

1.3 Margins

SCPS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SCPS Yearly Profit, Operating, Gross MarginsSCPS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021

More info and screens

0

2. Health

2.1 Basic Checks

SCPS has more shares outstanding than it did 1 year ago.
There is no outstanding debt for SCPS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SCPS Yearly Shares OutstandingSCPS Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 5M 10M 15M 20M
SCPS Yearly Total Debt VS Total AssetsSCPS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2M 4M 6M 8M

2.2 Solvency

SCPS has an Altman-Z score of -318.61. This is a bad value and indicates that SCPS is not financially healthy and even has some risk of bankruptcy.
SCPS has a Altman-Z score of -318.61. This is amonst the worse of the industry: SCPS underperforms 96.57% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -318.61
ROIC/WACCN/A
WACCN/A
SCPS Yearly LT Debt VS Equity VS FCFSCPS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 0 -5M -10M

2.3 Liquidity

SCPS has a Current Ratio of 0.07. This is a bad value and indicates that SCPS is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of SCPS (0.07) is worse than 96.72% of its industry peers.
A Quick Ratio of 0.07 indicates that SCPS may have some problems paying its short term obligations.
SCPS's Quick ratio of 0.07 is on the low side compared to the rest of the industry. SCPS is outperformed by 96.72% of its industry peers.
Industry RankSector Rank
Current Ratio 0.07
Quick Ratio 0.07
SCPS Yearly Current Assets VS Current LiabilitesSCPS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2M 4M 6M 8M

More info and screens

1

3. Growth

3.1 Past

SCPS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 40.08%, which is quite impressive.
EPS 1Y (TTM)40.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.22%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 3.63% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y8.21%
EPS Next 2Y-17.18%
EPS Next 3Y-2.21%
EPS Next 5Y3.63%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SCPS Yearly EPS VS EstimatesSCPS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SCPS. In the last year negative earnings were reported.
Also next year SCPS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SCPS Price Earnings VS Forward Price EarningsSCPS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SCPS Per share dataSCPS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1 -1.5

4.3 Compensation for Growth

SCPS's earnings are expected to decrease with -2.21% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-17.18%
EPS Next 3Y-2.21%

More info and screens

0

5. Dividend

5.1 Amount

SCPS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SCOPUS BIOPHARMA INC

NASDAQ:SCPS (12/16/2022, 8:25:53 PM)

After market: 0.12 -0.05 (-28.66%)

0.1682

-0.17 (-50.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)12-02 2022-12-02/bmo
Earnings (Next)N/A N/A
Inst Owners0%
Inst Owner Change0%
Ins Owners2.42%
Ins Owner Change0%
Market Cap3.55M
Revenue(TTM)N/A
Net Income(TTM)-16397840
Analysts82.86
Price Target12.24 (7177.05%)
Short Float %0.15%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.81
EYN/A
EPS(NY)-1.88
Fwd EYN/A
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)-0.56
OCFYN/A
SpS0
BVpS-0.26
TBVpS-0.26
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 83.78%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.07
Quick Ratio 0.07
Altman-Z -318.61
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.22%
EPS Next Y8.21%
EPS Next 2Y-17.18%
EPS Next 3Y-2.21%
EPS Next 5Y3.63%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-19.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-351.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-351.57%
OCF growth 3YN/A
OCF growth 5YN/A

SCOPUS BIOPHARMA INC / SCPS FAQ

Can you provide the ChartMill fundamental rating for SCOPUS BIOPHARMA INC?

ChartMill assigns a fundamental rating of 1 / 10 to SCPS.


Can you provide the valuation status for SCOPUS BIOPHARMA INC?

ChartMill assigns a valuation rating of 0 / 10 to SCOPUS BIOPHARMA INC (SCPS). This can be considered as Overvalued.


What is the profitability of SCPS stock?

SCOPUS BIOPHARMA INC (SCPS) has a profitability rating of 1 / 10.


What is the earnings growth outlook for SCOPUS BIOPHARMA INC?

The Earnings per Share (EPS) of SCOPUS BIOPHARMA INC (SCPS) is expected to grow by 8.21% in the next year.